Toxicological Effects of Antituberculosic Chemotherapy in Adults: An Integrative Literature Review
Journal of Pharmaceutical Research International,
Objective: To analyze the toxicological effects of anti-tuberculosis chemotherapy in adults in national and international literature in the period from 2015 to 2020.
Methodology: It is a qualitative descriptive research, of the type Integrative Literature Review (ILR). In the VHL databases PubMed / Medline, Arca, Web of Science, Microsoft Academic and Cochrane Library. Data analysis was performed with the aid of the IRaMuTeQ software.
Results: 36 articles were found in which the following categories were created: 1) Association of hepatotoxicity and appearance of liver damage; 2) The incidence of adverse events related to antituberculin therapy; 3) Risk factors of regular consumption of antituberculins; 4) Intensive renal treatment for patients with nephrotoxicity.
Conclusion: in our review we identified that the elderly, HIV positive and alcohol users are more likely to have toxicological effects during treatment, which can lead to a possible abandonment of treatment.
- antitubercular agents
- drug therapy
How to Cite
Chaves EC, Carneiro ICRS, Santos MIPO, Sarges NA, Neves EOS. Aspectos epidemiológicos, clínicos e evolutivos da tuberculose em idosos de um hospital universitário em Belém, Pará. Revista Brasileira de Geriatria e Gerontologia, Rio de Janeiro. 2017;20(1):47-58.
Silva LF,Silva EL, Silva TC, Caldas AJM. Tuberculose em idosos no Maranhão: contribuição para o programa de controle. Rev Fun Care Online. 2019;11(4):1088-1095.
Resende LSO, Santos-Neto ETS. Fatores associados às reações adversas a medicamentos antituberculose. J Bras Pneumol. 2015;41(1):77-89.
Olivência SA, Barbosa LGM, Cunha MR, Silva LJ. Tratamento farmacológico da dor crônica não oncológica em idosos: Revisão integrativa. Rev. bras. geriatr. gerontol.2018;21(3):383-393.
Pedrosa KKA, Oliveira ICM, Feijão AR, Machado RC. Enfermagem baseada em evidência: Caracterização dos estudos no Brasil. Cogitare Enferm. 2015;20(4):733-741.
Souza MAR, Wall ML, Thuler ACMC, Lowen IMV, Peres AM. O uso do software IRAMUTEQ na análise de dados em pesquisas qualitativas*. Rev Esc Enferm USP. 2018; 52(1): 1-7.
Salviati ME. Manual do Aplicativo Iramuteq (versão 0.7 Alpha 2 e R Versão 3.2.3); 2017.
Acesso em: 16 de agosto de 2020. Disponível em:
Song JH, Yoon SH, Park TY, Heo EY, Kim DK, Chung HS et al. The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study. Rev. Respiratory Research. 2019;20:283.
Jun CAO, Yijun MI, Cuilin SHI, Yicong BIAN, Chenrong HUANG, Zhijian YE. First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform. Biochem Biophys Res Commun 2018;497(2):485-491.
Vasconcelos KA, Frota SMMC, Netto AR, Kritski AR. Análise sequencial como ferramenta na detecção da ototoxicidade da amicacina no tratamento da tuberculose multirresistente. J Bras Pneumol. 2018;44(2):85-92.
Bouazzi OE, Hammi S, Bourkadi JE, Tebaa A, Tanani DS, Bencheikh RS, et al. First line anti-tuberculosis induced hepatotoxicity: Incidence and risk factors. Pan African Medical Journal. 2016;25-167.
Lee CM, Lee SS, Lee JM, et al. Early monitoring for detection of anti tuberculous drug-induced hepatotoxicity. The Korean Journal of Internal Medicine. 2016;31(1):65–72.
Cojutti P, Duranti S, Isola M, Baraldo M, Viale P, Bassetti M, Pea F. Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?. J Antimicrob Chemother. 2016;71(1):1323–1329.
Jeong I, Park JS, Cho YJ, Yoon HI, Song J, Lee CT et al. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. Rev. Korean Med Sci. 2015;30(1):167-172.
Lang SM, Ortmann J, Rostig S, Schiffl H. Ursodeoxycholic acid attenuates hepatotoxicity of multidrug treatment of mycobacterial Infections: A prospective pilot study. Rev. International Journal of Mycobacteriology. 2020;19(1).
Luangchosiri C, Thakkinstian A, Chitphuk S, Stitchantrakul W, Petraksa S, Sobhonslidsuk A. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. BMC Complementary and Alternative Medicine. 2015;15(1):334.
Russom M, Debesai M, Zeregabr M, Berhane A, Tekeste T, Teklesenbet T. Serious hepatotoxicity following use of isoniazid preventive therapy in HIV patients in Eritrea. Pharmacol Res Perspect; 2018.
Sharma SK, Jha BK, Sharma A, Sreenivas V, Upadhyay V, Jaisinghani C, et al. Genetic polymorphisms of N-acetyltransferase 2 & susceptibility to antituberculosis drug-induced hepato-toxicity. Indian J Med Res. 2016;924-928.
Shibeshi W, Sheth AN, Admasu A, Berha AB, Negash Z, Yimer G. Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: A retrospective cohort study. BMC Pharmacology and Toxicology. 2019;31 (20):1-10.
Usui T, Meng X, Saide K, Farrell J, Thomson P, Whitaker P. Characterization of isoniazid-specific T-cell clones in patients with anti-tuberculosis drug-related liver and skin injury. Rev. Toxicological sciences, 2017;155(2):420–431.
Valadares RMC, Carvalho WS, Miranda SS. Association of adverse drug reaction to anti-tuberculosis medication with quality of life in patients in a tertiary referral hospital. Rev. Soc. Bras. Med. Trop. on line. 2020;53.
Wang JY, Tsai CH, Lee YL, Lee LN, Hsu CL, Chang HC, et al. Gender-dimorphic impact of PXR genotype and haplotype on hepatotoxicity during antituberculosis treatment. Rev. Medicine. 2015;94(24).
Zhang J, Zhu X, Li Y, Zhu L, Li S, Zheng G. Correlation of CPG island methylation of the cytochrome P450 2E1/2D6 genes with liver injury induced by anti-tuberculosis drugs: A nested case-control study. Int. J. Environ. Res. Public Health. 2016;13:776.
Adole PS, Kharbanda P, Sharma S. N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - A pilot study. Rev. Indian J Med Res. 2016;143:581-590.
Altena RV, Dijkstra JA, Meer MEVD, Howard JFB, Kosterink JGW, Soolingen DV et al. Reduced chance of hearing loss associated with therapeutic drug monitoring of aminoglycosides in the treatment of multidrug-resistant tuberculosis. Rev Antimicrobial Agents and Chemotherapy. 2017;61(3):1-10.
Chan SL, Chua APG, Aminkeng F, Chee CBE, Jin S, Loh M. Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. Rev. Plos one; 2017.
Amagon KL, Awodele O, Akindele AJ. Methionine and vitamin B-complex ameliorate antitubercular drugs-induced toxicity in exposed patients. Rev. Noxious Effects of Antitubercular Drugs Modulated. 2017;5(5):360.
Jin KW, Lee JY, Rhiu S, Choi DG. Longitudinal evaluation of visual function and structure for detection of subclinical ethambutol-induced optic neuropathy. Rev. longitudinal evaluation of visual function and structure for detection of subclinical ethambutol-induced optic neuropathy. Rev. Plos one. 2019;1-12.
Taffner BMP, Mattos FB, Cunha MC, Saraiva FP. The use of optical coherence tomography for the detection of ocular toxicity by ethambutol. Rev. Plos one. 2018;1-10.
Tweed CD, Crook AM, Amukoye EL, Dawson R, Diacon AH, Hanekom M, et al. Toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Infectious Diseases. 2018;18:317.
Wiltshire CS, Braun AV, Scherrer AU, Manabe YC, Buzibye AMD, et al. Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients. J Antimicrob Chemother. 2017; 72(4):1172-1177.
Ngouleun W, Nya PCB, Pieme AC, Telefo PB. Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus/AIDS-coinfected patients under tuberculosis treatment. Rev. International Journal of Mycobacteriology. 2016;482–488.
Mariz CA, Lopes EP, Santos BA, Maruza M, Montarroyos UR, Ximenes RAA, et al. Hepatotoxicity during treatment for tuberculosis in people living with HIV/AIDS. Rev. PLoS One. 2016;11(6).
Sakashita K, Murata K, Takahashi Y, Yamamoto M, Oohashi K, Sato Y. A case series of acute kidney injury during anti-tuberculosis treatment. Intern Med 2019;58(4):521-527.
Sineke T, Evans D, Schnippel K, Aswegen HV, Berhanu R, Musakwa N. The impact of adverse events on healthrelated quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South. Health and Quality of Life Outcomes. 2019;17(1):94.
Jones J, Mudaly V, Voget J, Naledi T, Maartens G, Cohen K. Adverse drug reactions in South African patients receiving bedaquiline - containing tuber culosis treatment: An evaluation of spontaneously reported cases. BMC Infectious Diseases. 2019;19(1):544.
Isa SE, Ebonyi AO, Shehu NY, Idoko P, Okopi JAA, Simji G, et al. Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria. International Journal of My Cobacteriology. 2016: 21-26.
Abstract View: 0 times
PDF Download: 0 times